• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

By: Veradigm via Business Wire
February 20, 2024 at 08:01 AM EST

Using de-identified data for 53 million unique cardiovascular patients, the report examines prevalence across all 50 states and a variety of demographics

Which region of the U.S. has the highest rates of hypertension, coronary artery disease and heart failure? The South, according to this analysis on cardiovascular disease (CVD) from Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions. Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients. The report explores the prevalence of CVD and underlying conditions across all 50 states and a variety of demographics, including age, ethnicity, and sex.

Using structured and unstructured data from the comprehensive Veradigm Network EHR dataset, the report presents cardiovascular condition prevalence by state and three-digit zip code. Veradigm also examines the prevalence of cardiovascular conditions such as dyslipidemia/hyperlipidemia and hypertension in relation to body mass index (BMI) categories.

Findings in this report are derived from the Veradigm Network EHR database, which connects over 400,000 healthcare providers and 200 million patients. It incorporates structured and unstructured data using Natural Language Processing (NLP) on approximately 100,000 U.S.-based healthcare practitioners and over 145 million patients with clinical activity.

“Veradigm is using NLP to extract typically inaccessible unstructured and semi-structured data. This has been quite impactful for left ventricle ejection fraction (LVEF),” said Machaon Bonafede, Vice President of Real-World Evidence at Veradigm. “NLP on unstructured clinical notes provides LVEF data on approximately 200,000 additional patients compared to what we can find in structured fields alone. This type of insight can help improve management of patients with cardiovascular disease and add clinical depth to our research.”

In the report, LVEF data pulled from unstructured clinical notes revealed almost 20,000 patients with possible heart failure and almost 30,000 with low function in the dataset. This type of previously inaccessible insight can help improve management of patients with cardiovascular disease and offers implications for early intervention.

“Cardiovascular disease is the leading cause of death across most segments of the population – men, women, and people of most racial and ethnic groups – in the U.S.,” said Stuart Green, Veradigm’s Senior Vice President and General Manager of Life Sciences. “Findings from Veradigm’s repository of de-identified data provides a larger story about the state of cardiovascular disease in the United States. We believe this data can help healthcare organizations to better understand geographic prevalence of cardiovascular disease and provide an entry point to data that isn’t typically accessible from other sources. This report affirms Veradigm’s role as a leader of this important and impactful data.”

The data in this report were selected and mapped for states and 3-digit zip codes for a subset of 53 million patients in the Veradigm Network EHR database with evidence of cardiovascular risk factors or conditions. Veradigm has a variety of additional data sources including clinically enriched Veradigm Network EHR Data across various therapeutic areas and the Veradigm Cardiovascular and Metabolic Registries.

To download the report and learn more about the research, please visit: Veradigm Insights Report: Cardiovascular Conditions in 2024.

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

© 2024 Veradigm Inc. and/or its affiliates. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220938851/en/

Contacts

Investors:

Jenny Gelinas

312-506-1237

jenny.gelinas@veradigm.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@veradigm.com

More News

View More
MarketBeat Week in Review – 10/27 - 10/31
Today 7:00 EDT
Via MarketBeat
Tickers AMZN AVGO CARR FUN GOOGL INTC
Amazon Earnings: 3 Catalysts That Could Drive Shares to $300
October 31, 2025
Via MarketBeat
Tickers AMZN GOOG GOOGL
Why Chipotle Stock May Bounce After a Brutal Sell-Off
October 31, 2025
Via MarketBeat
Tickers CMG
Why VGT May Be a Smarter Bet Than Chasing Individual Tech Stocks
October 31, 2025
Via MarketBeat
Tickers AAPL AVGO MSFT NVDA VGT
Equinix Stock Rises Despite Lower Revenue Guidance
October 31, 2025
Via MarketBeat
Tickers EQIX META MSFT

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap